C188-9 compound: Clinical Trials

3 trials of C188-9 compound, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting, 1 withdrawn. 3 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Completed 1, Recruiting 1, Withdrawn 1
Phase 12Recruiting 1, Withdrawn 1

Follow C188-9 compound: new trials by email Literature Review of C188-9 compound trials Research Report on C188-9 compound

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)
TTI-101, Pembrolizumab - Head and Neck Squamous Cell Carcinoma
Phase 1 / Phase 2WithdrawnM.D. Anderson Cancer Center2025-09-232025-12-17
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
TTI-101, Placebo - Idiopathic Pulmonary Fibrosis
Phase 2CompletedTvardi Therapeutics, Incorporated1002023-05-152026-08-13
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
TTI-101, Pembrolizumab, Atezolizumab - Hepatocellular Carcinoma
Phase 1 / Phase 2RecruitingTvardi Therapeutics, Incorporated1932023-03-232026-10-22

Conditions studied

Carcinoma, Hepatocellular (1)  ·  Idiopathic Pulmonary Fibrosis (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)

Sponsors

Tvardi Therapeutics, Incorporated (2)  ·  M.D. Anderson Cancer Center (1)

Countries

United States (2)

Top investigators

Faye Johnson, MD (1)